- Home
- IPAR vs ACAD Comparison
IPAR vs ACAD Comparison
Compare IPAR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPAR
- ACAD
- Stock Information
- Founded
- IPAR 1982
- ACAD 1993
- Country
- IPAR United States
- ACAD United States
- Employees
- IPAR N/A
- ACAD N/A
- Industry
- IPAR Package Goods/Cosmetics
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- IPAR Consumer Discretionary
- ACAD Health Care
- Exchange
- IPAR Nasdaq
- ACAD Nasdaq
- Market Cap
- IPAR 3.1B
- ACAD 3.5B
- IPO Year
- IPAR 1988
- ACAD 2004
- Fundamental
- Price
- IPAR $89.41
- ACAD $22.74
- Analyst Decision
- IPAR Strong Buy
- ACAD Buy
- Analyst Count
- IPAR 5
- ACAD 21
- Target Price
- IPAR $154.60
- ACAD $29.43
- AVG Volume (30 Days)
- IPAR 238.5K
- ACAD 2.0M
- Earning Date
- IPAR 11-05-2025
- ACAD 11-05-2025
- Dividend Yield
- IPAR 3.49%
- ACAD N/A
- EPS Growth
- IPAR 14.29
- ACAD 615.00
- EPS
- IPAR 5.02
- ACAD 1.33
- Revenue
- IPAR $1,458,888,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- IPAR $4.18
- ACAD $14.01
- Revenue Next Year
- IPAR $5.35
- ACAD $12.00
- P/E Ratio
- IPAR $18.27
- ACAD $17.00
- Revenue Growth
- IPAR 7.04
- ACAD 14.41
- 52 Week Low
- IPAR $91.06
- ACAD $13.40
- 52 Week High
- IPAR $148.15
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- IPAR 33.87
- ACAD 52.32
- Support Level
- IPAR $91.06
- ACAD $22.05
- Resistance Level
- IPAR $100.73
- ACAD $23.05
- Average True Range (ATR)
- IPAR 2.71
- ACAD 0.80
- MACD
- IPAR 0.16
- ACAD 0.29
- Stochastic Oscillator
- IPAR 15.36
- ACAD 76.30
About IPAR Inter Parfums Inc.
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations.. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.